<?xml version='1.0' encoding='utf-8'?>
<document id="24212378"><sentence text="In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold."><entity charOffset="97-117" id="DDI-PubMed.24212378.s1.e0" text="dabigatran etexilate" /></sentence><sentence text="Dabigatran etexilate, an oral, reversible, competitive, and direct thrombin inhibitor, is an in vitro and in vivo substrate of P-glycoprotein (P-gp)"><entity charOffset="0-20" id="DDI-PubMed.24212378.s2.e0" text="Dabigatran etexilate" /></sentence><sentence text=" Dabigatran etexilate was proposed as an in vivo probe substrate for intestinal P-gp inhibition in a recent guidance on drug-drug interactions (DDI) from the European Medicines Agency (EMA) and the Food and Drug Administration (FDA)"><entity charOffset="1-21" id="DDI-PubMed.24212378.s3.e0" text="Dabigatran etexilate" /></sentence><sentence text=" We conducted transcellular transport studies across Caco-2 cell monolayers with dabigatran etexilate in the presence of various P-gp inhibitors to examine how well in vitro IC50 data, in combination with mathematical equations provided by regulatory guidances, predict DDI likelihood"><entity charOffset="81-101" id="DDI-PubMed.24212378.s4.e0" text="dabigatran etexilate" /></sentence><sentence text=" From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine"><entity charOffset="42-56" id="DDI-PubMed.24212378.s5.e0" text="clarithromycin" /><entity charOffset="58-71" id="DDI-PubMed.24212378.s5.e1" text="cyclosporin A" /><entity charOffset="73-85" id="DDI-PubMed.24212378.s5.e2" text="itraconazole" /><entity charOffset="87-99" id="DDI-PubMed.24212378.s5.e3" text="ketoconazole" /><entity charOffset="101-110" id="DDI-PubMed.24212378.s5.e4" text="quinidine" /><entity charOffset="116-125" id="DDI-PubMed.24212378.s5.e5" text="ritonavir" /><entity charOffset="163-183" id="DDI-PubMed.24212378.s5.e6" text="dabigatran etexilate" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e0" e2="DDI-PubMed.24212378.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e1" e2="DDI-PubMed.24212378.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e1" e2="DDI-PubMed.24212378.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e1" e2="DDI-PubMed.24212378.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e1" e2="DDI-PubMed.24212378.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e1" e2="DDI-PubMed.24212378.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e1" e2="DDI-PubMed.24212378.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e2" e2="DDI-PubMed.24212378.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e2" e2="DDI-PubMed.24212378.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e2" e2="DDI-PubMed.24212378.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e2" e2="DDI-PubMed.24212378.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e2" e2="DDI-PubMed.24212378.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e3" e2="DDI-PubMed.24212378.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e3" e2="DDI-PubMed.24212378.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e3" e2="DDI-PubMed.24212378.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e3" e2="DDI-PubMed.24212378.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e4" e2="DDI-PubMed.24212378.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e4" e2="DDI-PubMed.24212378.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e4" e2="DDI-PubMed.24212378.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e5" e2="DDI-PubMed.24212378.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24212378.s5.e5" e2="DDI-PubMed.24212378.s5.e6" /></sentence><sentence text=" IC50 values of P-gp inhibitors for dabigatran etexilate transport were comparable to those of digoxin, a well established in vitro and in vivo P-gp substrate"><entity charOffset="36-56" id="DDI-PubMed.24212378.s6.e0" text="dabigatran etexilate" /><entity charOffset="95-102" id="DDI-PubMed.24212378.s6.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.24212378.s6.e0" e2="DDI-PubMed.24212378.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24212378.s6.e0" e2="DDI-PubMed.24212378.s6.e1" /></sentence><sentence text=" However, IC50 values varied depending whether they were calculated from efflux ratios or permeability coefficients" /><sentence text=" Prediction of DDI likelihood of P-gp inhibitors using IC50 values, the hypothetical concentration of P-gp inhibitors, and the cut-off value recommended by both the FDA and EMA were in line with the DDI occurrence in clinical studies with dabigatran etexilate"><entity charOffset="239-259" id="DDI-PubMed.24212378.s8.e0" text="dabigatran etexilate" /></sentence><sentence text=" However, it has to be kept in mind that validity of the cut-off criteria proposed by the FDA and EMA depends on in vitro experimental systems and the IC50-calculation methods that are employed, as IC50 values are substantially influenced by these factors" /><sentence text=" " /></document>